Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab + SGN-B6A |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | head and neck squamous cell carcinoma | predicted - sensitive | Pembrolizumab + SGN-B6A | Phase I | Actionable | In a Phase I trial (SGNB6A-001), SGN-B6A and Keytruda (pembrolizumab) combination treatment demonstrated safety and activity in patients with CD274 (PD-L1)-positive (CPS >=1) head and neck squamous cell carcinoma, resulting in a confirmed overall response rate of 37.5% (3/8) with 2 confirmed complete response and 1 confirmed partial response (J Clin Oncol 2025 43: 16_suppl, 3122; NCT04389632). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study (SGNB6A-001). | Full reference... |